VALIDOGEN, formerly known as VTU Technology, is a leading Austrian contract research and development company. VALIDOGEN offers UNLOCK PICHIA - the broadest toolbox and most versatile technology platform available for Pichia pastoris recombinant protein production. Founded in 2008, the company emerged to a globally recognized player in the field of Pichia pastoris based protein expression. VALIDOGEN has established a broad range of tools and know-how for the generation of high-performance Pichia processes. Exclusive proprietary technologies and profound experience of the VALIDOGEN team lead to competitive production processes for a wide range of recombinant proteins. Headquartered in Raaba-Grambach, near Graz, Austria, VALIDOGEN is a private company and independent subsidiary of the KonValue Holding GmbH.
Bio-ferm is active in R
Vivaldi Biosciences is developing its DeltaFLU influenza vaccine to provide broad cross-protection and superior efficacy in the prophylaxis of seasonal and pandemic influenza. DeltaFLU is composed of influenza vaccine strains genetically modified by deletion of the gene for nonstructural protein 1.
Planta was founded in 1994 by three dynamic biotechnologists whose aim was to put their ideas and visions into practice. Today Planta is an innovative drug development company. Our staff members’ academic backgrounds lie in the fields of biochemistry, biology, pharmacology and toxicology. Our permanent key personal consists of seven co-workers – a group which allows for a compact and familiar atmosphere. Flexibility is our strength and is a great asset to our customers and cooperation partners.
BlueSky Immunotherapies GmbH (Ltd.) is a clinical-stage biotech company. The company’s business is based on its own proprietary, novel technology platform for interferon-inducing viral vectors (delNS). Interferons have immunostimulatory and antiviral properties. BlueSky uses these delNS- mediated properties for therapies against cancer and viral infectious diseases.
Unsere Experten im Bereich Life Science unterstützen Wissenschaftler und Ingenieure dabei, die Herausforderungen in jedem Entwicklungsstadium ihrer Arbeit zu meistern. Unser Angebot umfasst fortschrittlichste Technologien sowie hochwertige Produkte und Lösungen. Anwendung finden diese in der F
Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions. With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.
ViraTherapeutics develops a new class of immunotherapy drugs based on oncolytic (cancer-destroying) viruses. Our patent protected virus is designed to be safe for human beings and efficiently destroys cancer cells, while leaving normal tissues unharmed. ViraTherapeutics currently performs preclinical safety and efficacy studies for our modified Vesicular Stomatitis Virus (VSV-GP) and aims to conduct first clinical trials in cancer patients in the near future.
AOP Orphan Pharmaceuticals AG is an international pharmaceutical company with a focus on rare and special diseases. Over the past 25 years, the company has become an established provider of integrated therapy solutions from its headquarters in Vienna. This has been made possible by a high level of investment in research and development and a strong orientation towards the needs of especially the patients and their families but also the doctors and health care professionals.
F4 Pharma, a clinical-stage biopharmaceutical company developing F06, an anti-inflammatory therapeutic that has shown to improve vascular integrity, FX06 is a substance discovered and developed in the Medical University of Vienna and has a dual mode of action: it is reducing the capillary leak and has anti-inflammatory efficacy. In Covid-19 by reducing pulmonary vascular hyperpermeability, FX06 is supposed to lead to improved lung function and reduced time of mechanical ventilation.
QPS is a global contract research organization (CRO) providing discovery, preclinical and clinical drug development services since 1995. Our mission is to accelerate pharmaceutical breakthroughs across the globe by delivering custom-built research services. An award-winning leader focused on bioanalysis and clinical trials, QPS is known for proven quality standards, technical expertise, a flexible approach to research, client satisfaction and turnkey laboratories and facilities.
Bayer has core competencies in the fields of health care and nutrition. We address the challenges presented by a growing and aging global population and are committed to drive sustainable development, generate a positive impact with our businesses and create value through innovation and growth. Bayer Austria is a subsidiary of Bayer AG, based in Vienna, where about 190 employees are responsible for marketing, sales, medical information on Bayer-products and clinical studies.
GSK is a leading global research-driven healthcare company with approximately 94,000 employees in 96 countries. At GSK Austria, about 80 employees are working to make a wide range of prescription drugs and vaccines available to as many people as possible in Austria - focusing on transformative therapies in oncology, severe asthma and HIV. For the seventh year in a row, GSK is number one in the Access to Medicine Index and GSK Austria is a member of Transparency International Austria.
AstraZeneca Österreich GmbH is one of the leading pharmaceutical companies in Austria and develops, manufactures and markets innovative drugs for the treatment of diseases in the fields of cardiovascular and metabolism, oncology, respiratory diseases and for the treatment of infectious and autoimmune diseases.